Using the chromogenic substrate S-2222, we have optimized and automated an amidolytic assay for heparin. The assay is based on the detection of anti-Xa activity generated by hepann in plasma. The method is reproducible (intra-and interassay CVs of 2.4 and 3.3%, respectively) and reliable in antithrombin Ill-deficient plasma. Results of this assay, obtained for plasma samples from patients and volunteers treated with heparin, correlate well (r = 0.899) with those of the test for activated partial thromboplastin time. Upon administration of a IOWMr hepannoid (Org 10172) and heparin fragment (Kabi 2165), however, the activated partial thromboplastin time failed to detect anticoagulant activity, whereas the chromogenic heparin assay revealed anti-Xa activity. This automated amidolytic assay for heparin is therefore suitable not only for monitonng standard therapy with heparin but also for measuring the activity of recently developed hepann fractions.
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The main action of heparin on the coagulation system is to enhance the biological activity of the main coagulation (1) and of a heparinoid (2, 3) requires another kind of therapy monitoring, because these substances exert specific anti-Xa activity without appreciable effect on, and hence detection by, clotting tests (3. 4) . The development of chromogenic substrates has made feasible the selective measurement of heparin-potentiated anti-Xa activity of ATifi in plasma (5) (6) (7) . For dose-adjustment studies with these new heparins, therefore, automated methods that are convenient and reliable and have a large throughput are desirable.
Moreover, an automated assay for anti-Xa would reduce costs, allow large-scale monitoring of patients (e.g., those undergoing hemodialysis, cardiac surgery with extracorporeal circulation, or thrombosis treatment), and improve accuracy.
Here we report the optimization of a chromogenic assay for anti-Xa activity and discuss its application in patients 
Materials and Methods

Materials
Venous blood samples were collected in polystyrene tubes containing as anticoagulant either 1 mL of trisodium citrate dihydrate (0.12 mmol/L) or 15 mg of solid K2EDTA per 10 mL of blood. Citrated blood was centrifuged at 2400 x g for 10 mm at room temperature;
to obtain platelet-poor plasma, we recentrifuged these samples at 13 000 x g for 4 mm at room temperature.
Blood containing EDTA was directly rendered platelet-poor by centrifugation at 13 000 X g. Blood was also collected in tubes containing 0.30 mL of "Edinburgh cocktail," prepared from equal volumes of Na2EDTA (100 gIL) prostaglandin E1 (30 molIL), and theophylline (30.0 mmolIL). Platelet-rich plasma was obtained by centrifuging citrated blood at 340 x g for 10 miii at room temperature.
The pooled plasma used for comparisons was prepared by pooling platelet-poor citrated-plasma samples from 40 healthy subjects (equal numbers of both sexes), then freezing small aliquots at -70 #{176}C.
Bovine factor Xa, chromogenic substrate 5-2222, and human AT-rn concentrate (Coatest#{174}/Heparinkit) were obmined from KabiVitrum B.V. Diagnostica, Amsterdam, The Netherlands.
We dissolved one vial of factor Xa in 10 mL of distilled water, obtaining an activity of 7.1 zkat/L (1 pkat = 60 U). We also obtained blood from six patients (three men and three women) on chronic hemodialysis. Their ages were 47-72 years (mean 57), and their weights ranged from 42.8 to 72.4 kg (mean 55.1). They received no medication interfering with hemostasis. All participants were informed of the experiment according to the Convention of Helsinki-Tokyo before the study, and the study was approved by the Scientific and Medical-Ethical
Committees of the University Hospital.
Procedures
Prepanuion of standards.
Mix 30 L of the pooled plasma with 0.10 mL of AT-ifi solution and increasing quantities of heparin, Org 10172, or Kabi 2165 to final concentrations ranging from 0 to 800 mt. units/L. Adjust the final volume of each standard to 0.50 mL with buffer. Figure 1 illustrates a representative standard curve. We estimated the potency of each heparin or related compound by comparison with a standard curve prepared from the specific product given to a patient.
Assay. Table 1 summarizes the steps of both the manual and automated assay procedures. For the latter we used an Automated Kinetic Enzyme and Substrate Analyzer (Vitatron, Dieren, The Netherlands).
For the manual determination of anti-Xa activity, we used a Model 550 spectrophotometer with a thermostated cuvet holder and connected to a Coleman 5-120 enzyme calculator, which was started with If the anti-Xa activity recorded exceeds 800 mt. unitsfL, we dilute the plasma with the pooled plasma and re-test.
Determination of activated partial thromboplastin time (APTT).
For comparison, we determined APTF with use of kaolin (10, 11) . We dissolved 0.10 g of lecithin in 100 mL of barbital buffer and stored 1-mL aliquots at -20 #{176}C. Washed kaolin, 4 g, was suspended in 100 mL of NaC1, 150 mmol/L, and stored at 4#{176}C. Equal volumes of lecithin and kaolin preparations were mixed just before starting the assay.
After diluting 0.10 mL of citrated plasma with 0.10 mL of barbital buffer, we added 0.10 mL of the lecithin/kaolin suspension and incubated for 6 mm at 37#{176}C. We then added 0.1 mL of CaC12 (33 mmol/L) and determined the clotting endpoint visually. 
Results
Assay Optimization and Characteristics
Influence of anticoagulant.
We collected 37 venous blood samples from four heparin-treated patients, using collection tubes containing either citrate or EDTA. After correction of the measured anti-Xa activities for differences in hematocrit as previously described (12) , the correlation between the activities determined in EDTA-treated and citrated plasma was quite good (r = 0.965).
Influence of different concentrations of supplemental
AT-III and Xa. We used different concentrations 
Influence of the concentration of AT-Ill in the test sample.
To investigate the effect of variations in the plasma AT-rn content on the assay results, we compared standard curves prepared with either the pooled normal plasma, containing about 1000 PEU of AT-rn per liter, or plasma from a patient with a severe AT-Ill deficiency (110 PEU/L). No significant differences were observed within a heparin concentration range of 300-800 mt. unitsfL. At lower heparin concentrations, however, there were some differences ( Figure 5 ).
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Increasing the initial AT-rn concentration to 300 PEU/L corrected the discrepancy between the normal standard curve and the AT-rn-deficient standard curve, confirming that this discrepancy was caused by the different concentrations of AT-rn in plasma.
Influence of platelets.
To investigate the effects of disruption of platelets, either in the course of blood sampling or during further handling of the samples, we performed the following experiments: a) Four persons were injected with 2500 mt. units of heparmn ("Thromboliquine"). U/i.. release of heparin-neutralizing Platelet Factor 4 after blood sampling. c) To eliminate disruption of platelets (accidently present in the test plasma) during freezing and thawing of plasma as a source of artificial reduction of anti-Xa activity, we performed the following experiment.
To part of a preparalion of platelet-rich plasma (385 x i09 platelets per liter) we added two amounts of heparin (final concentrations 200 and 600 mt. unitsfL). The other part of the platelet-rich plasma was centrifuged at 13 000 x g for 4 mm, after which the supernate was similarly mixed with heparin and used as a control. Both platelet-rich and control plasma were freezethawed twice and subsequently assayed in duplicate for anti-Xa activity.
We prepared the standard curve for this comparison from citrated plasma from the same blood donor. Table 3 sunmiarizes the results for anti-Xa activity.
Influence of temperature.
Anti-Xa activities in heparinized (200 or 600 int. unitsfL) plasma after centrifugation at room temperature or at 4#{176}C did not differ (data not shown). Moreover, anti-Xa activity in heparinized platelet-poor plasma (same heparin concentrations) incubated at room temperature or on melting ice for 2 h was no less than that of fresh platelet-poor plasma (data not shown).
Influence of bilirubin. Addition of as much as 500 mg per liter of bilirubin to pooled plasma samples containing 600 hit. units of heparin per liter did not alter the anti-Xa values (data not shown).
Clinical Studies
Six male volunteers were injected with a single intravenous dose of 5000 mt. units of heparmn, 3500 anti-Xa units of Org 10172, or 5000 anti-Xa units of Kabi 2165. As Figure 6 shows, the anti-Xa activities and the APT'F values determined at intervals after the administration of heparin were highly correlated (r = 0.899).
In volunteers receiving
Org 10172 the AP'ITF changed little, whereas the chromogenic assay revealed a distinct increase in anti-Xa activity. Thus the correlation between the anti-Xa assay and the AP'lTF was poor (r = 0.105).
Similar results
were obtained for the heparin fragment Kabi 2165, the correlation between the two methods being r = 0.372. For six patients subjected to hemodialysis with either Org 10172 or heparin, we monitored the anti-Xa activity with the chromogenic assay. A representative experiment (Figure 7) showed almost no effect of Org 10172 on the AP'lTF,in contrast to the effect of heparin. Nevertheless, at these anti-
Xa activities,
there was no clotting in the extracorporeal circuit. and (c), in contrast to other reports (7), there was no effect of temperature on heparin recovery. Therefore we do not recommend the routine use of additional platelet-release inhibitors to reduce heparin-neutralizing activity, as suggested by others (7) .
The use of a "Venoject" blood-sampling system apparently does not cause measurable loss of anti-Xa activity, which improves the value of this assay as a practical clinical test.
In conclusion, the main advantages of this automated assay for anti-Xa activity are its practical application in routine determination of heparin activity and its potential for determining anti-Xa activity of new heparin derivatives, which will be increasingly used in clinical practice.
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